Quel est le prix pour Handa Pharmaceuticals, Inc. (6620)

Le prix pour Handa Pharmaceuticals, Inc. (6620) est $2.95

Quelle est la capitalisation boursière pour Handa Pharmaceuticals, Inc. (6620)

La capitalisation boursière pour Handa Pharmaceuticals, Inc. (6620) est $491.95M

Revenus de Handa Pharmaceuticals, Inc. (6620)

Handa Pharmaceuticals, Inc. operates as a specialized drug company, concentrating its efforts on creating and advancing new medications for diverse health issues across both the United States and China. The firm currently offers Quetiapine XR, a treatment for Schizophrenia, as well as Dexlansoprazole DR capsules. Beyond its existing portfolio, Handa is actively cultivating a robust pipeline of therapies. This includes their cutting-edge ONCORE drug delivery platform, engineered to boost patient adherence and improve the safety of tyrosine kinase inhibitor oncology drugs. Other significant projects encompass a 505(b)(2)NDA therapeutic agent, Tascenso ODT for managing multiple sclerosis, and the oncology candidates HND-033 and HND-027. Furthermore, the company's development initiatives feature HND-004, designed for diabetic patients; HND-032, intended to aid in smoking cessation; and HND-026, a gastrointestinal medication. Founded in 2014, Handa Pharmaceuticals, Inc. has its main corporate headquarters situated in Tainan City, Taiwan.

Année	Revenus	Changez
Pas assez de données pour les dates fournies.

Année

Revenus

Changez

Pas assez de données pour les dates fournies.

Entreprise	Revenus	Différence de revenus	Pays
MERCK Kommanditgesellschaft auf Aktien MER.SW	-	-	DE
Merck KGaA MRK.DE	-	-	DE
Takeda Pharmaceutical Company Limited 4502.T	-	-	JP
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	$6.61B	-	IN
Galderma Group AG GALD.SW	-	-	CH

Entreprise

Revenus

Différence de revenus

Pays